natgillin/translations-raw huggingface dataset:
In clinical trials sildenafil was administered to more than 8000 patients aged 19-87.
V kliničnih študijah je sildenafil dobivalo več kot 8000 bolnikov, starih od 19 do 87 let.
In clinical trials Synflorix elicited an immune response to all ten serotypes included in the vaccine, but the magnitude of the responses varied between serotypes.
V kliničnih preskušanjih je cepivo Synflorix izzvalo imunski odziv na vseh deset serotipov v cepivu, toda velikost odziva se je med serotipi razlikovala.
In clinical trials the efficacy of ceftolozane/tazobactam was lower in patients with moderate renal impairment compared with those with normal or mildly impaired renal function at baseline.
V kliničnih preskušanjih je bila učinkovitost ceftolozana/tazobaktama pri bolnikih z zmerno okvaro ledvic manjša v primerjavi z bolniki z normalnim delovanjem ledvic ali blago okvaro ledvic v izhodišču.
In clinical trials the following reactions were reported at a ≥ 1 % difference in frequency from placebo: vertigo, nausea, pain in limb, dizziness, depression, dyspnoea.
V kliničnih preskušanjih so z ≥ 1 % razliko v pogostnosti od placeba poročali o naslednjih reakcijah: vrtoglavica, slabost, bolečina v okončinah, omotica, depresija, dispneja.
In clinical trials the most frequently reported ocular adverse reactions following injection of Macugen are: anterior chamber inflammation, eye pain, increased intraocular pressure, punctate keratitis, vitreous floaters and vitreous opacities.
V kliničnih preskušanjih so po injiciranju zdravila Macugen najpogosteje poročali o naslednjih očesnih neželenih učinkih: vnetje sprednjega prekata, bolečina v očesu, zvišan očesni tlak, točkasti keratitis, motnjave v steklovini in delci v steklovini.
In clinical trials the number of herpes zoster/herpes zoster-like rashes within the 42-day postvaccination was low in both ZOSTAVAX and placebo groups.
V kliničnih preskušanjih je bilo število primerov herpesa zostra/herpesu zostru podobnih izpuščajev v 42 dneh po cepljenju majhno tako med prejemniki cepiva ZOSTAVAX kot med prejemniki placeba.
In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/l.
V kliničnih preskušanjih so bile te bolnice določene na podlagi ravni endogenega LH v serumu < 1,2 i.e./l.
In clinical trials with 553 patients, the most common adverse reactions were:
V kliničnih preskušanjih s 553 bolniki sta bila najpogostejša neželena učinka:
In clinical trials with Ameluz, local skin reactions at the application site were observed in up to 96% of the subjects.
V kliničnih študijah z zdravilom Ameluz so pri največ 96 % bolnikov opazili lokalne reakcije na koži na mestu nanosa.
In clinical trials with AMMONAPS, 56 % of the patients experienced at least one adverse event and 78 % of these adverse events were considered as not related to AMMONAPS.
V kliničnih preskušanjih z zdravilom AMMONAPS je 56 % bolnikov doživelo najmanj en neželeni dogodek, vendar se za 78 % teh neželenih dogodkov smatra, da niso povezani z zdravilom AMMONAPS.
In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo.
Med kliničnimi preskušanji aripiprazola v primerjavi s placebom niso ugotovili pomembnih razlik v incidenci hiperglikemičnih neželenih učinkov (vključno z diabetesom) ali nenormalnih laboratorijskih vrednosti glukoze v krvi.
In clinical trials with Avastin, congestive heart failure (CHF) was observed in all cancer indications studied to date, but occurred predominantly in patients with metastatic breast cancer.
V kliničnih preskušanjih z zdravilom Avastin so kongestivno srčno popuščanje opazili pri vseh indikacijah raka, ki so jih preiskovali do sedaj, pojavilo pa se je predvsem pri bolnikih z metastatskim rakom dojk.
In clinical trials with bazedoxifene monotherapy, somnolence was reported as an adverse reaction, and patients should be advised on the potential effect on driving and using machines.
V kliničnih preskušanjih z monoterapijo z bazedoksifenom so poročali o zaspanosti kot neželenem učinku, zato je treba bolnice opozoriti na možne učinke na sposobnost vožnje in upravljanja s stroji.
In clinical trials with different formulations (H5N3, H9N2 and H5N1) approximately 3400 subjects were exposed to the candidate vaccine.
V kliničnih preskušanjih z različnimi oblikami (H5N3, H9N2 in H5N1) je bilo modelnim cepivom izpostavljenih približno 3400 oseb.
In clinical trials with different formulations (H5N3, H9N2 and H5N1) approximately 3400 subjects were exposed to the mock-up vaccines.
V kliničnih preskušanjih z različnimi oblikami (H5N3, H9N2 in H5N1) je bilo modelnim cepivom izpostavljenih približno 3.400 oseb.
In clinical trials with eltrombopag in SAA, 4% of patients (5/133) were diagnosed with MDS.
V kliničnih študijah z eltrombopagom pri bolnikih s hudo aplastično anemijo so mielodisplastični sindrom odkrili pri 4 % bolnikov (5/133).
In clinical trials with OPTISON, undesirable effects were reported as adverse events with the following frequencies given in the table below: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
V kliničnih preskušanjih s kontrastnim sredstvom OPTISON so o neželenih učinkih poročali z naslednjimi pogostnostmi, ki so navedene v spodnji preglednici: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
In clinical trials with oral olanzapine, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥ 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF<500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
V kliničnih preskušanjih s peroralnim olanzapinom so bila klinično pomembna podaljšanja QTc (QT korekcija Fridericia [QTcF] ≥ 500 milisekund [msek] kadarkoli nad osnovno vrednostjo pri bolnikih z osnovno vrednostjo QTcF < 500 msek) pri bolnikih, zdravljenih z olanzapinom, redka (od 0,1 % do 1 %), brez pomembnih razlik v spremljajočih srčnih dogodkih v primerjavi z bolniki, zdravljenimi s placebom.
In clinical trials with pazopanib, events of cardiac dysfunction such as congestive heart failure and decreased left ventricular ejection fraction (LVEF) have occurred (see section 4.8).
V kliničnih preskušanjih s pazopanibom so se pojavile manifestacije motenega delovanja srca, npr. kongestivno srčno popuščanje in zmanjšanje iztisnega deleža levega prekata (LVEF) (glejte poglavje 4.8).
In clinical trials with pioglitazone, the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups.
V kliničnih preskušanjih s pioglitazonom je bila pojavnost zvišanj vrednosti ALT na več kot trikratno zgornjo mejo normalnih vrednosti enaka kot pri placebu, a manjša kot v primerjalnih skupinah z metforminom ali s sulfonilsečnino.
In clinical trials with pioglitazone, there was evidence of dose-related weight gain, which may be due to fat accumulation and, in some cases, associated with fluid retention.
V kliničnih preskušanjih pioglitazona so opazili od odmerka odvisno povečanje telesne mase, ki je lahko posledica kopičenja maščobe, v nekaterih primerih pa je lahko povezano z zastajanjem tekočine.
In clinical trials with ribavirin used in combination with peginterferon alfa-2b or interferon alfa-2b, the maximum overdose reported was a total dose of 10 g of ribavirin (50 x 200 mg capsules) and 39 MIU of interferon alfa-2b (13 subcutaneous injections of 3 MIU each) taken in one day by a patient in an attempt at suicide.
V kliničnih preskušanjih ribavirina v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b so poročali o prevelikem odmerku 10 g ribavirina (50 x 200 mg kapsul) in 39 mio i.e. interferona alfa- 2b (13 subkutanih injekcij po 3 mio i.e. vsaka), ki ga je v enem dnevu vzel bolnik v poskusu samomora.
In clinical trials with sodium phenylbutyrate, 56 % of the patients experienced at least one adverse event and 78 % of these adverse events were considered as not related to sodium phenylbutyrate.
V kliničnih preskušanjih z natrijevim fenilbutiratom je 56 % bolnikov doživelo najmanj en neželeni dogodek, vendar se za 78 % teh neželenih dogodkov šteje, da niso povezani z natrijevim fenilbutirat.
In clinical trials with tadalafil 5mg taken once a day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported more frequently in patients over 75 years of age.
V kliničnih preskušanjih, v katerih so bolniki jemali tadalafil 5 mg enkrat na dan za zdravljenje benigne hiperplazije prostate, so o omotici in diareji pogosteje poročali pri bolnikih nad 75. letom starosti.
In clinical trials with trametinib monotherapy one case of accidental overdose was reported; a single dose of 4 mg.
V kliničnih preskušanjih s trametinibom v monoterapiji je bil opisan en primer naključnega prevelikega odmerjanja z enkratnim odmerkom 4 mg.
In clinical trials with TRAVATAN, the most common adverse reactions were ocular hypearemia and iris hyperpigmentation, occurring in approximately 20% and 6% of patients respectively.
V kliničnih preskušanjih z zdravilom TRAVATAN sta bila najpogostejša neželena učinka očesna hiperemija in hiperpigmentacija šarenice, ki sta se pojavila pri 20% oziroma 6% bolnikov.
In clinical trials with vedolizumab at doses ranging from 2 to 10 mg/kg, >95% saturation of α4β7 receptors on subsets of circulating lymphocytes involved in gut immune surveillance was observed in patients.
V kliničnih preskušanjih so pri odmerkih vedolizumaba v razponu od 2 do 10 mg/kg pri bolnikih opazili > 95 % nasičenost α4β7 receptorjev pri podskupini limfocitov v obtoku, vključenih v črevesni imunski nadzor.
In clinical trials with zoledronic acid, patients with serum creatinine > 265 micromol/l or > 3.0 mg/dl were excluded.
V klinične študije niso vključevali bolnikov s serumskim kreatininom > 265 mikromolov/l ali > 3,0 mg/dl.
In clinical trials with zoledronic acid, patients with serum creatinine > 265 µmol/l or > 3.0 mg/dl were excluded.
Bolniki s serumskim kreatininom > 265 μmol/l ali > 3,0 mg/dl so bili iz kliničnih preskušanj z zoledronsko kislino izključeni
In clinical trials with zoledronic acid, patients with serum creatinine > 265 μmol/l or > 3.0 mg/dl were excluded.
Bolniki s serumskim kreatininom > 265 µmol/l ali > 3,0 mg/dl so bili iz kliničnih preskušanj z zoledronsko kislino izključeni.
In clinical trials with Zometa, patients with serum creatinine
Bolniki s serumskim kreatininom > 265 µmol/l ali
In clinical trials with ZYPADHERA the incidence of injection site related adverse reactions was approximately 8%.
V kliničnih preskušanjih z zdravilom ZYPADHERA je bila incidenca neželenih učinkov, povezanih z mestom injiciranja, približno 8 %.
In clinical trials, 2.8 % of FORSTEO patients had serum uric acid concentrations above the upper limit of normal compared with 0.7 % of placebo patients.
V kliničnih preskušanjih je imelo 2,8 % bolnikov, ki so prejemali zdravilo FORSTEO, serumske koncentracije sečne kisline nad zgornjo mejo normalnih vrednosti v primerjavi z 0,7 % bolnikov, ki so prejemali placebo.
In clinical trials, 3 patients out of a total of 2,560 patients treated with Tecfidera experienced serious flushing symptoms that were probable hypersensitivity or anaphylactoid reactions.
V kliničnih preskušanjih so 3 bolniki od skupaj 2.560 bolnikov, zdravljenih z zdravilom Tecfidera, doživeli resne simptome vročinskega oblivanja, ki so bili verjetno preobčutljivostne ali anafilaktoidne reakcije.
In clinical trials, 40% of patients treated with TRISENOX experienced at least one QT corrected (QTc) interval prolongation greater than 500 msec.
V kliničnih preskušanjih je pri 40 % bolnikov, ki so jih zdravili z zdravilom TRISENOX, prišlo do vsaj enega podaljšanja popravljenega intervala Q-T (Q-Tc), ki je trajal več kot 500 ms.
In clinical trials, 96 % of 1,497 healthy infants, children, adolescents and adults given a 3 dose course of a previous formulation of Merck’s recombinant hepatitis B vaccine developed a protective level of antibodies against hepatitis B virus surface antigen ( 10 IU/l).
V kliničnih raziskavah se je zaščitna raven protiteles proti površinskemu antigenu virusa hepatitisa B (≥ 10 i.e./l) pojavila pri 96 % od 1497 zdravih dojenčkov, otrok, mladostnikov in odraslih, ki so dobili ciklus treh odmerkov prejšnjega pripravka Merckovega rekombinantnega cepiva proti hepatitisu B.
In clinical trials, 97 % of patients who responded had a complete response at doses of ≤ 2.4 MIU (24 μg)/kg/day.
V kliničnih preskušanjih so pri 97 % bolnikov, ki so se odzvali na zdravljenje, zabeležili popoln odgovor na odmerke v vrednosti ≤ 2,4 x 106i.e. (24 μg)/kg/dan.
In clinical trials, 97% of patients who responded had a complete response at doses 24 micrograms/kg/day.
V kliničnih preskušanjih je imelo 97 % bolnikov, ki so se odzvali na zdravljenje, popoln odziv pri odmerkih  24 mikrogramov/kg/dan.
In clinical trials, a higher incidence of HFSR was observed in Asian (in particular Japanese) patients treated with Stivarga as compared with Caucasians (see section 4.2).
V kliničnih preskušanjih so opazili večjo incidenco HFSR pri bolnikih azijske rase (predvsem Japoncih), zdravljenih z zdravilom Stivarga, v primerjavi z belci (glejte poglavje 4.2).
In clinical trials, a higher incidence of severe liver function test abnormalities and hepatic dysfunction was observed in Asian (in particular Japanese) patients treated with Stivarga as compared with Caucasians (see section 4.2).
V kliničnih preskušanjih so večjo incidenco resnih nenormalnosti v izvidih preiskav delovanja jeter in moteno delovanje jeter opazili pri bolnikih azijske rase (predvsem pri Japoncih) zdravljenih z zdravilom Stivarga, v primerjavi z belci (glejte poglavje 4.2).
In clinical trials, a higher incidence of severe liver injury with fatal outcome was observed in Japanese patients (~1.5%) treated with Stivarga compared with non- Japanese patients (<0.1%).
V kliničnih preskušanjih so večjo incidenco hude okvare jeter s smrtnim izidom opazili pri japonskih bolnikih (~1,5 %), zdravljenih z zdravilom Stivarga, v primerjavi z nejaponskimi bolniki (<0,1 %).
In clinical trials, a patient’s anti-thyroid peroxidase (anti-TPO) antibody status prior to treatment was not indicative for the development of a thyroid related adverse event.
V kliničnih preskušanjih bolnikovo stanje protiteles proti encimu tiroidni peroksidazi (anti-TPO) pred zdravljenjem ni bilo bistveno za pojav na ščitnico vezanih neželenih dogodkov.
In clinical trials, a treatment time of 2-3 months with Clomicalm in combination with behavioural modification techniques was sufficient to control the symptoms of separation-related disorders.
S kliničnimi poskusi so dokazali, da je 2-3 mesečno zdravljenje, kombinirano s terapijo vedenjskih motenj, uspešno za odpravo določenih simptomov le- teh.
In clinical trials, a treatment time of 2-3 months with Clomicalm in combination with behavioural modification techniques was sufficient to control the symptoms of separation-related disorders.
S kliničnimi poskusi so dokazali, da je 2-3 mesečno zdravljenje, kombinirano s terapijo vedenjskih motenj, uspešno za odpravo določenih simptomov le-teh.
In clinical trials, acute pancreatitis has been reported in association with dulaglutide (see section 4.8).
V kliničnih preskušanjih so o akutnem pankreatitisu poročali v povezavi z dulaglutidom (glejte poglavje 4.8).
In clinical trials, acute pancreatitis has been reported in association with Eperzan (see section 4.8).
V kliničnih preskušanjih so poročali o akutnem pankreatitisu v povezavi z zdravilom Eperzan (glejte poglavje 4.8).
In clinical trials, approximately 7% of patients experienced an adverse drug reaction associated with the use of Emadine; however, less than 1% of these patients discontinued therapy due to these adverse drug reactions.
V kliničnih preskušanjih je imelo približno 7% bolnikov neželene učinke ob uporabi zdravila Emadine, vendar je manj kot 1% teh bolnikov prenehalo z zdravljenjem zaradi omenjenih neželenih učinkov.
In clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo.
V kontroliranih kliničnih preskušanjih s priporočenim odmerkom 5 mg na dan pri bolnikih niso opažali povečane incidence zaspanosti v primerjavi s placebom.
In clinical trials, background therapies included metformin, a sulfonylurea, a thiazolidinedione, or a combination of oral glucose-lowering medicinal products.
Osnovna zdravljenja so v kliničnih študijah obsegala metformin, sulfonilsečnino, tiazolidindion ali kombinacijo peroralnih zdravil za zniževanje glukoze.
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF]
V kliničnih preskušanjih so bila klinično pomembna podaljšanja QTc (QT korekcija Fridericia [QTcF]
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF]
V kliničnih preskušanjih so bila klinično pomembna podaljšanja QTc (QT korekcija Fridericia [QTcF] ≥ 500 milisekund [msek] kadarkoli nad osnovno vrednostjo pri bolnikih z osnovno vrednostjo
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥
V kliničnih preskušanjih so bila klinično pomembna podaljšanja QTc (QT korekcija Fridericia [QTcF]
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥ 500 milliseconds [msec] at any time post baseline in patients with baseline
V kliničnih preskušanjih so bila klinično pomembna podaljšanja QTc (QT korekcija Fridericia [QTcF] ≥ 500 milisekund [msek] kadarkoli nad osnovno vrednostjo pri bolnikih z osnovno vrednostjo
In clinical trials, decreased systolic blood pressure (> 35 mm Hg) was observed in 7% of patients and decreased diastolic blood pressure (> 25 mm Hg) was observed in 4% of patients within 45 minutes of Rapiscan administration.
V kliničnih študijah so pri 7% bolnikov opazili znižan sistolični krvni tlak (> 35 mm Hg) in pri 4% bolnikov znižan diastolični krvni tlak (> 25 mm Hg), ki sta se pojavila v 45 minutah po dajanju zdravila Rapiscan.
In clinical trials, decreases in left ventricular ejection fraction (LVEF) of 20% and below the lower limit of normal occurred in approximately 2% of sunitinib-treated GIST patients, 4% of cytokine-refractory MRCC patients, and 2% of placebo-treated GIST patients.
V kliničnih preskušanjih se je zmanjšanje iztisnega deleža levega prekata (LVEF) za  20 % in pod spodnjo mejo normale med zdravljenjem s sunitinibom pojavilo pri približno 2 % bolnikov z GIST in 4 % bolnikov z MRCC, odpornem proti citokinom, med uporabo placeba pa pri 2 % bolnikov z GIST.
In clinical trials, doses of elosulfase alfa were explored up to 4 mg/kg per week and no specific signs or symptoms were identified following the higher doses.
V kliničnih preskušanjih so raziskali elosulfazo alfa v odmerku do 4 mg/kg na teden in po višjih odmerkih niso ugotovili nobenih specifičnih znakov ali simptomov.
In clinical trials, efficacy was demonstrated against gastro-enteritis due to rotavirus of the most common genotypes G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8].
V kliničnih preskušanjih so dokazali učinkovitost proti gastroenteritisu, ki ga povzročajo rotavirusi najpogostejših genotipov G1P8, G2P4, G3P8, G4P8 in G9P8.
In clinical trials, elevations 3-fold the upper limit of normal (ULN) or greater in ALT occurred in 8.0% of patients treated with fingolimod 0.5 mg compared to 1.9% of placebo patients.
V kliničnih študijah je do zvišanja vrednosti alanin-aminotransferaze na trikratnik zgornje meje normalnih vrednosti (ZMN) ali več prišlo pri 8,0 % bolnikov, ki so prejemali fingolimod 0,5 mg, v primerjavi z 1,9 % bolnikov, ki so prejemali placebo.
In clinical trials, general safety has been evaluated in more than 57000 adults vaccinated with ZOSTAVAX.
V kliničnih preskušanjih so splošno varnost ocenili pri več kot 57.000 odraslih, cepljenih s cepivom ZOSTAVAX.
In clinical trials, interactions between Kineret and other medicinal products (including nonsteroidal anti-inflammatory medicinal products, corticosteroids, and DMARDs) have not been observed.
V kliničnih preskušanjih niso opazili interakcij med zdravilom Kineret in drugimi zdravili (vključno z nesteroidnimi protivnetnimi zdravili, kortikosteroidi in DMARD).
In clinical trials, no interactions have been observed when Enbrel was administered with glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate.
Med kliničnimi preizkušanji niso opazili nobenih interakcij med zdravilom Enbrel in glukokortikoidi, salicilati (razen sulfasalazina), nesteroidnimi protivnetnimi zdravili (NSAIDs), analgetiki ali metotreksatom.
In clinical trials, no interactions have been observed when etanercept was administered with glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate.
Med kliničnimi preizkušanji niso opazili nobenih interakcij med etanerceptom in glukokortikoidi, salicilati (razen sulfasalazina), nesteroidnimi protivnetnimi zdravili (NSAIDs), analgetiki ali metotreksatom.
In clinical trials, no PNH or aHUS patients experienced an infusion reaction which required discontinuation of Soliris.
V kliničnih preskušanjih ni imel noben bolnik s PNH ali z aHUS takšne reakcije na infuzijo, ki bi zahtevala prekinitev zdravljenja z zdravilom Soliris.
In clinical trials, NovoThirteen has been administered to 56 patients with congenital factor XIII A- subunit deficiency (1043 doses of NovoThirteen).
V kliničnih preskušanjih je zdravilo NovoThirteen prejemalo 56 bolnikov s prirojenim pomanjkanjem podenote A faktorja XIII (1043 odmerkov zdravila NovoThirteen).
In clinical trials, one case of plasmacytoma at injection site was observed in a patient who was found to have multiple myeloma.
V kliničnih preskušanjih so opazili en primer plazmacitoma na mestu injiciranja pri bolniku, za katerega se je izkazalo, da ima diseminirani plazmocitom.
In clinical trials, ONIVYDE was administered at doses up to 240 mg/m2 to patients with various cancers.
V kliničnih preskušanjih so zdravilo ONIVYDE dajali v odmerkih do 240 mg/m2 bolnikom z različnimi vrstami raka.
In clinical trials, Optruma did not stimulate the postmenopausal uterine endometrium.
V kliničnih preskušanjih zdravilo Optruma ni stimuliralo postmenopavzalnega materničnega endometrija.
In clinical trials, oral contraceptives (e.g. the pill) did not reduce the protection obtained by Cervarix.
V kliničnih preskušanjih peroralni kontraceptivi (kontracepcijske tablete) niso zmanjšali zaščite, pridobljene s cepivom Cervarix.
In clinical trials, oral or other contraceptives (e.g. the pill) did not reduce the protection obtained by Silgard.
Med kliničnimi preskušanji peroralni ali drugi kontraceptivi (npr. kontracepcijske tablete) niso zmanjšali zaščite, dosežene s cepivom Silgard.
In clinical trials, over 1,566 patients received Pravafenix.
V kliničnih študijah je zdravilo Pravafenix prejelo 1566 bolnikov.
In clinical trials, over 5,700 patients received Pelzont alone or with an HMG-CoA reductase inhibitor.
V kliničnih preskušanjih je zdravilo Pelzont samo ali skupaj z zaviralcem reduktaze HMG-CoA dobivalo več kot 5.700 bolnikov.
In clinical trials, over 5,700 patients received Tredaptive alone or with an HMG-CoA reductase inhibitor.
V kliničnih preskušanjih je zdravilo Tredaptive samo ali skupaj z zaviralcem reduktaze HMG-CoA dobivalo več kot 5.700 bolnikov.
In clinical trials, over 7,900 depressed patients have received Thymanax.
Zdravilo Thymanax je v kliničnih preskušanjih jemalo več kot 7.900 bolnikov z depresijo.
In clinical trials, over 7,900 depressed patients have received Valdoxan.
Zdravilo Valdoxan je v kliničnih preskušanjih jemalo več kot 7.900 bolnikov z depresijo.